FDA Inspections, Warning Letters & Emerging cGMP Compliance Issues

8 years ago
150 Views
“Our mission is to increase understanding in order to influence public policy and protect natural supplements”.
FDA Inspections, Warning Letters & Emerging cGMP Compliance Issues
Hello

As a business owner, AHPA’s upcoming webinar will help you better understand the intricacies of cGMP guidelines. AHPA’s content isextremely relevant due to the recent spate of FDA inspections that have been occurring. We highly suggest you attend on Tuesday Dec. 13th.

Thank you,
BEA

An insider’s view of the current cGMP enforcement landscape

Event Details

Date: Tuesday, Dec. 13

Time: 1:00-3:00 PM EST

Cost:
Members – $199
Non-Members – $499

Materials:
Webinar recording
Presenter slides
Presenter biographies

This webinar is designed to help businesses in the dietary supplement industry understand the elements of 21 CFR 111 / current Good Manufacturing Practices (cGMP) regulations that have been the focus of recent FDA inspections. This knowledge will assist business to ascertain their own compliance status.
Veteran industry legal experts will provide attendees with an insider’s view of the current cGMP enforcement landscape. AHPA staff will offer a detailed analysis of the association’s repository of inspection data, widely regarded as the most in-depth in the industry. That analysis is based on actual FDA 483 Notices of Observations and establishment inspection reports (EIRs). A summary of the AHPA’s data collection process, a review of the data and detailed examples will also be provided.
A 20-30-minute Q&A session will follow the speaker presentations to answer specific questions about FDA inspections, enforcement actions, and related matters.

Topics

  • Click here to submit questions anonymously BEFORE the webinar so that presenters can address YOUR ISSUES during their presentation
  • Manufacturer vs. contract manufacturer vs. supplier vs. brand marketer: What are the differences and what aspects of the cGMP are you responsible for during an inspection?  And what is FDA looking for?
  • FDA “Hot buttons” during inspections and what can be done to prepare and mitigate
  • Statistics compiled from FDA 483s.
  • How to appropriately respond to a Form FDA 483 to head off a Warning Letter
  • Answers to your questions during the Q&A session

Presenters

  • Anthony L. Young, Esq., Partner, Kleinfeld, Kaplan and Becker, LLP / AHPA General Counsel
  • Merle Zimmermann, Ph.D., Chief Information Analyst, AHPA
  • Jennifer M. Adams, Esq., Associate, Amin Talati & Upadhye

For more news, connect with AHPA on social media:
        

You may also like